A Phase 2 interventional study of Glycopyrrolate Inhalation Solution12.5μg and Glycopyrrolate Inhalation Solution 50μg in Chronic Obstructive Pulmonary Disease, sponsored by Sunovion Respiratory Development Inc.. Completed. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-03-12.
Sponsored by Sunovion Respiratory Development Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Pulmonary Disease, Chronic Obstructive by Sumitomo Pharma Co., Ltd. — none open to participants now, none under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · Sumitomo Pharma Co., Ltd..
Among the 24 studies in Pulmonary Disease, Chronic Obstructive by Sumitomo Pharma Co., Ltd., this one is the 20th largest by enrollment, is the only one that started in 2010, is one of 7 in phase 2, and was the 22nd registered.
5,526 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →None of the 24 studies in Pulmonary Disease, Chronic Obstructive by Sumitomo Pharma Co., Ltd. is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years to 75 Years · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42 is below the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 225 across the 24 interventional studies. Of the 24 that completed or were terminated, 15 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Sunovion Respiratory Development Inc., one of the names counted as Sumitomo Pharma Co., Ltd.. Under that name alone:
Sunovion Respiratory Development Inc. is the lead sponsor of 10 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 24 studies in Pulmonary Disease, Chronic Obstructive by Sumitomo Pharma Co., Ltd., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study assessed the safety and ability of an orally inhaled medicine [i.e., Glycopyrrolate Inhalation Solution = GIS] to improve airflow in the lungs when delivered using an eFlow nebulizer in 42 patients with Chronic Obstructive Pulmonary Disease (COPD). Each patient randomly received several, single doses of GIS, or placebo, separated by approximately 1 to 2 weeks. After the dose was given, lung airflow was measured over 24 hours and blood was collected to measure how much GIS was in the bloodstream. The study was conducted to find the once-a- day GIS dose that produced the highest improvement in lung airflow using the eFlow nebulizer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Females who are pregnant or lactating at the Screening Visit, or if of not using one of the following acceptable means of throughout the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Glycopyrrolate Inhalation Solution12.5μg via e-flow nebulizer, once daily
Drug: Glycopyrrolate Inhalation Solution12.5μg
Glycopyrrolate Inhalation Solution 50mg via e-flow nebulizer, once daily
Drug: Glycopyrrolate Inhalation Solution 50μg
Glycopyrrolate Inhalation Solution 100μg via e-flow nebulizer, once daily
Drug: Glycopyrrolate Inhalation Solution 100μg
Glycopyrrolate Inhalation Solution 200μg via e-flow nebulizer, once daily
Drug: Glycopyrrolate Inhalation Solution 200μg
Glycopyrrolate Inhalation Solution 400μg via e-flow nebulizer, once daily
Drug: Glycopyrrolate Inhalation Solution 400μg
Placebo 0.5mL via e-flow nebulizer, once daily
Drug: Placebo 0.5mL
Glycopyrrolate Inhalation Solution12.5μg via eFlow, once daily
Also known as: GIS
Glycopyrrolate Inhalation Solution 50μg via eFlow, once daily
Also known as: GIS
Glycopyrrolate Inhalation Solution 100μg via eFlow, once daily
Also known as: GIS
Glycopyrrolate Inhalation Solution 200μg via eFlow, once daily
Also known as: GIS
Glycopyrrolate Inhalation Solution 400μg via eFlow, once daily
Also known as: GIS
Placebo 0.5mL via eFlow, once daily
Also known as: Placebo
Trough FEV1 (Change From Baseline)
Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. Trough FEV1 was defined as the mean of FEV1 values obtained at 23 hours 30 minutes and 24 hours post-dose of each Treatment Visit.
Time frame: 24hr post dose
Standardized FEV1AUC0-12 Area Under the FEV1 Curve From 0 to 12 Hours Post-dose ( Actual and Change From Baseline).
Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines.. The standardized actual FEV1 AUC(0-12) was calculated using the trapezoidal rule divided by the actual hours from the first FEV1 to the last FEV1 in the interval. Standardized change from baseline FEV1 AUC(0-12) was also calculated similarly, using the change from pre-dose FEV1.
Time frame: 0-12h post dose
Standardized FEV1AUC12-24 Area Under the FEV1 Curve From 12 to 24 Hours Post- Dose (Actual and Change From Baseline).
Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. The standardized actual FEV1 AUC(12-24) was calculated using the trapezoidal rule divided by the actual hours from the first FEV1 to the last FEV1 in the interval. Standardized change from baseline FEV1 AUC(12-24) was also calculated similarly, using the change from pre-dose FEV1.
Time frame: 12-24h post dose
Standardized FEV1 AUC0-24 Area Under the FEV1 Curve From 0 to 24 Hours Post-dose (Actual and Change Baseline)
Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. . The standardized actual FEV1 AUC(0-24) was calculated using the trapezoidal rule divided by the actual hours from the first FEV1 to the last FEV1 in the interval. Standardized change from baseline FEV1 AUC(0-24) was also calculated similarly, using the change from pre-dose FEV1.
Time frame: 0 to 24h
Peak FEV1 (Change From Baseline and Percent Change)
spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. . The peak FEV1 was defined as the highest post-dose FEV1 value within 4 hrs after the dose. Percent change from baseline was calculated as 100 times the difference of peak FEV1 minus baseline FEV1 divided by baseline FEV1.
Time frame: 0-4h post dose
Cmax; Maximum Observed Plasma Concentration
Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr
Time frame: 0 to 12 hour
Tmax; Time to Maximum Observed Plasma Concentration
Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr
Time frame: 0 to 12 hours
t1/2; Plasma Half-life
Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr
Time frame: 0 to 12 hour
AUC0-t; Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Measurable Drug Concentration.
Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr
Time frame: 0 to 12 hour
AUC0-inf Area Under the Plasma Concentration-time Curve From Time Zero to Infinity
Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr
Time frame: 0 to 12 hour
Number of Subjects Who Died, Number of Subjects With Treatment Emergent SAEs, Number of Subjects Who Discontinued Due to AE
AE's are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment
Time frame: Day 69 (includes dosing Day 1, washout Day 12, safety follow up Day 69)
Number of Subjects With Clinically Significant Abnormal Vital Signs Reported During the Study
Vital signs were measured at screening and at each Treatment Visit pre-dose (within 30 minutes prior to dose); post-dose at 30 minutes and 1, 2, 4, 8, 12 and 24 hours; and then at the post study assessment.
Time frame: 0-24 h
Number of Clinically Significant Abnormal Laboratory Results Reported During the Study
Clinical safety lab parameters were collected at screening and at the post study assessment. Any laboratory values that were out of range of normal reference values were evaluated by the Investigators.
Time frame: Day -14, Day 69
Number of Subjects With Clinically Significant ECG Parameters Reported During the Study
ECGs were recorded at screening and at each study treatment visit pre-dose (within 30 minutes prior to dose); post-dose at 30 minutes and 1, 2, 4, 8, 12 and 24 hours; and then at the post study assessment.
Time frame: 0 to 24h
Percentage of Subjects With Treatment Emergent AEs
AE's are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment
Time frame: Day 69 (includes dosing Day 1, washout Day 12, safety follow up Day 69)
| Milestone | Treatment Group 1 | Treatment Group 2 | Treatment Group 3 | Treatment Group 4 | Treatment Group 5 | Treatment Group 6 |
|---|---|---|---|---|---|---|
| Started | 7 | 7 | 7 | 7 | 7 | 7 |
| Completed | 7 | 7 | 7 | 7 | 7 | 7 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Treatment Group 1 | Treatment Group 2 | Treatment Group 3 | Treatment Group 4 | Treatment Group 5 | Treatment Group 6 |
|---|---|---|---|---|---|---|
| Started | 7 | 7 | 7 | 7 | 7 | 7 |
| Completed | 7 | 5 | 7 | 7 | 7 | 6 |
| Not completed | 0 | 2 | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 1 |
| Milestone | Treatment Group 1 | Treatment Group 2 | Treatment Group 3 | Treatment Group 4 | Treatment Group 5 | Treatment Group 6 |
|---|---|---|---|---|---|---|
| Started | 7 | 5 | 7 | 7 | 7 | 6 |
| Completed | 7 | 5 | 7 | 7 | 7 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Treatment Group 1 | Treatment Group 2 | Treatment Group 3 | Treatment Group 4 | Treatment Group 5 | Treatment Group 6 |
|---|---|---|---|---|---|---|
| Started | 7 | 5 | 7 | 7 | 7 | 6 |
| Completed | 7 | 4 | 7 | 6 | 7 | 6 |
| Not completed | 0 | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Personal reasons | 0 | 0 | 0 | 1 | 0 | 0 |
| Milestone | Treatment Group 1 | Treatment Group 2 | Treatment Group 3 | Treatment Group 4 | Treatment Group 5 | Treatment Group 6 |
|---|---|---|---|---|---|---|
| Started | 7 | 4 | 7 | 6 | 7 | 6 |
| Completed | 7 | 4 | 7 | 6 | 7 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Treatment Group 1 | Treatment Group 2 | Treatment Group 3 | Treatment Group 4 | Treatment Group 5 | Treatment Group 6 |
|---|---|---|---|---|---|---|
| Started | 7 | 4 | 7 | 6 | 7 | 6 |
| Completed | 7 | 4 | 7 | 6 | 7 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Treatment Group 1 | Treatment Group 2 | Treatment Group 3 | Treatment Group 4 | Treatment Group 5 | Treatment Group 6 |
|---|---|---|---|---|---|---|
| Started | 7 | 4 | 7 | 6 | 7 | 6 |
| Completed | 7 | 4 | 7 | 6 | 7 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Treatment Group 1 | Treatment Group 2 | Treatment Group 3 | Treatment Group 4 | Treatment Group 5 | Treatment Group 6 |
|---|---|---|---|---|---|---|
| Started | 7 | 4 | 7 | 6 | 7 | 6 |
| Completed | 6 | 4 | 6 | 6 | 7 | 6 |
| Not completed | 1 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 1 | 0 | 0 | 0 |
| Milestone | Treatment Group 1 | Treatment Group 2 | Treatment Group 3 | Treatment Group 4 | Treatment Group 5 | Treatment Group 6 |
|---|---|---|---|---|---|---|
| Started | 6 | 4 | 6 | 6 | 7 | 6 |
| Completed | 6 | 4 | 6 | 6 | 7 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Treatment Group 1 | Treatment Group 2 | Treatment Group 3 | Treatment Group 4 | Treatment Group 5 | Treatment Group 6 |
|---|---|---|---|---|---|---|
| Started | 6 | 4 | 6 | 6 | 7 | 6 |
| Completed | 6 | 4 | 6 | 6 | 7 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Treatment Group 1 | Treatment Group 2 | Treatment Group 3 | Treatment Group 4 | Treatment Group 5 | Treatment Group 6 |
|---|---|---|---|---|---|---|
| Started | 6 | 4 | 6 | 6 | 7 | 6 |
| Completed | 6 | 4 | 6 | 6 | 7 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Treatment Group 1 | Treatment Group 2 | Treatment Group 3 | Treatment Group 4 | Treatment Group 5 | Treatment Group 6 |
|---|---|---|---|---|---|---|
| Started | 6 | 4 | 6 | 6 | 7 | 6 |
| Completed | 6 | 4 | 6 | 6 | 7 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. Trough FEV1 was defined as the mean of FEV1 values obtained at 23 hours 30 minutes and 24 hours post-dose of each Treatment Visit.
| liters | Glycopyrrolate Inhalation Solution12.5μg | Glycopyrrolate Inhalation Solution 50μg | Glycopyrrolate Inhalation Solution 100μg | Glycopyrrolate Inhalation Solution 200μg | Glycopyrrolate Inhalation Solution 400μg | Placebo 0.5mL |
|---|---|---|---|---|---|---|
| Trough FEV1 (Change From Baseline) | -0.093 ± 0.1189 | 0.0114 ± 0.1308 | 0.0447 ± 0.1548 | 0.0542 ± 0.1779 | 0.0292 ± 0.1468 | -0.0612 ± 0.1233 |
Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines.. The standardized actual FEV1 AUC(0-12) was calculated using the trapezoidal rule divided by the actual hours from the first FEV1 to the last FEV1 in the interval. Standardized change from baseline FEV1 AUC(0-12) was also calculated similarly, using the change from pre-dose FEV1.
| liters | Glycopyrrolate Inhalation Solution12.5μg | Glycopyrrolate Inhalation Solution 50μg | Glycopyrrolate Inhalation Solution 100μg | Glycopyrrolate Inhalation Solution 200μg | Glycopyrrolate Inhalation Solution 400μg | Placebo 0.5mL |
|---|---|---|---|---|---|---|
| actual standardized FEV1 AUC0_12 | 1.259 ± 0.409 | 1.311 ± 0.422 | 1.335 ± 0.394 | 1.374 ± 0.391 | 1.390 ± 0.423 | 1.180 ± 0.427 |
| change from baseline standardized FEV1 AUC0_12 | 0.055 ± 0.113 | 0.126 ± 0.112 | 0.136 ± 0.134 | 0.184 ± 0.134 | 0.170 ± 0.110 | -0.024 ± 0.095 |
Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. The standardized actual FEV1 AUC(12-24) was calculated using the trapezoidal rule divided by the actual hours from the first FEV1 to the last FEV1 in the interval. Standardized change from baseline FEV1 AUC(12-24) was also calculated similarly, using the change from pre-dose FEV1.
| liters | Glycopyrrolate Inhalation Solution12.5μg | Glycopyrrolate Inhalation Solution 50μg | Glycopyrrolate Inhalation Solution 100μg | Glycopyrrolate Inhalation Solution 200μg | Glycopyrrolate Inhalation Solution 400μg | Placebo 0.5mL |
|---|---|---|---|---|---|---|
| acutal standardized FEV1 AUC0_12 | 1.165 ± 0.377 | 1.203 ± 0.404 | 1.227 ± 0.369 | 1.253 ± 0.346 | 1.259 ± 0.396 | 1.123 ± 0.392 |
| change from baseline standardized FEV1 AUC0_12 | -0.038 ± 0.132 | 0.018 ± 0.135 | 0.028 ± 0.138 | 0.063 ± 0.178 | 0.039 ± 0.135 | -0.082 ± 0.120 |
Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. . The standardized actual FEV1 AUC(0-24) was calculated using the trapezoidal rule divided by the actual hours from the first FEV1 to the last FEV1 in the interval. Standardized change from baseline FEV1 AUC(0-24) was also calculated similarly, using the change from pre-dose FEV1.
| liters | Glycopyrrolate Inhalation Solution12.5μg | Glycopyrrolate Inhalation Solution 50μg | Glycopyrrolate Inhalation Solution 100μg | Glycopyrrolate Inhalation Solution 200μg | Glycopyrrolate Inhalation Solution 400μg | Placebo 0.5mL |
|---|---|---|---|---|---|---|
| Actual standardized FEV1 AUC0_12 | 1.212 ± 0.391 | 1.257 ± 0.411 | 1.281 ± 0.379 | 1.313 ± 0.364 | 1.325 ± 0.407 | 1.151 ± 0.408 |
| change from baseline standardized FEV1 AUC0_12 | 0.009 ± 0.114 | 0.072 ± 0.115 | 0.082 ± 0.128 | 0.123 ± 0.146 | 0.105 ± 0.113 | -0.053 ± 0.102 |
spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. . The peak FEV1 was defined as the highest post-dose FEV1 value within 4 hrs after the dose. Percent change from baseline was calculated as 100 times the difference of peak FEV1 minus baseline FEV1 divided by baseline FEV1.
| liters | Glycopyrrolate Inhalation Solution12.5μg | Glycopyrrolate Inhalation Solution 50μg | Glycopyrrolate Inhalation Solution 100μg | Glycopyrrolate Inhalation Solution 200μg | Glycopyrrolate Inhalation Solution 400μg | Placebo 0.5mL |
|---|---|---|---|---|---|---|
| Change from baseline | 0.165 ± 0.113 | 0.229 ± 0.113 | 0.260 ± 0.151 | 0.292 ± 0.120 | 0.272 ± 0.125 | 0.061 ± 0.102 |
| percent change from baseline | 15.30 ± 11.37 | 21.05 ± 11.87 | 24.14 ± 20.69 | 26.73 ± 12.56 | 25.44 ± 15.10 | 5.24 ± 8275 |
Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr
| pg/mL | Glycopyrrolate Inhalation Solution12.5μg | Glycopyrrolate Inhalation Solution 50μg | Glycopyrrolate Inhalation Solution 100μg | Glycopyrrolate Inhalation Solution 200μg | Glycopyrrolate Inhalation Solution 400μg |
|---|---|---|---|---|---|
| Cmax; Maximum Observed Plasma Concentration | 59.25 ± 78.49 | 74.48 ± 62.24 | 144.58 ± 52.53 | 316.05 ± 48.35 | 504.93 ± 55.67 |
Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr
| hours | Glycopyrrolate Inhalation Solution12.5μg | Glycopyrrolate Inhalation Solution 50μg | Glycopyrrolate Inhalation Solution 100μg | Glycopyrrolate Inhalation Solution 200μg | Glycopyrrolate Inhalation Solution 400μg |
|---|---|---|---|---|---|
| Tmax; Time to Maximum Observed Plasma Concentration | 0.165 (0.150 to 0.180) | 0.320 (.0150 to 0.350) | 0.260 (0.150 to 0.330) | 0.275 (0.150 to 0.380) | 0.180 (0.150 to 0.320) |
Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr
| hours | Glycopyrrolate Inhalation Solution12.5μg | Glycopyrrolate Inhalation Solution 50μg | Glycopyrrolate Inhalation Solution 100μg | Glycopyrrolate Inhalation Solution 200μg | Glycopyrrolate Inhalation Solution 400μg |
|---|---|---|---|---|---|
| t1/2; Plasma Half-life | — | 0.8949 ± 2.3707 | 3.0137 ± 50.7557 | 3.1663 ± 45.4839 | 4.1238 ± 63.5353 |
Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr
| pg.h/ml | Glycopyrrolate Inhalation Solution12.5μg | Glycopyrrolate Inhalation Solution 50μg | Glycopyrrolate Inhalation Solution 100μg | Glycopyrrolate Inhalation Solution 200μg | Glycopyrrolate Inhalation Solution 400μg |
|---|---|---|---|---|---|
| AUC0-t; Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Measurable Drug Concentration. | 135.87 ± 209.27 | 67.18 ± 143.22 | 237.80 ± 98.45 | 677.24 ± 66.34 | 1481.36 ± 82.17 |
Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr
| pg.h/ml | Glycopyrrolate Inhalation Solution12.5μg | Glycopyrrolate Inhalation Solution 50μg | Glycopyrrolate Inhalation Solution 100μg | Glycopyrrolate Inhalation Solution 200μg | Glycopyrrolate Inhalation Solution 400μg |
|---|---|---|---|---|---|
| AUC0-inf Area Under the Plasma Concentration-time Curve From Time Zero to Infinity | — | 246.84 ± 37.49 | 634.65 ± 34.28 | 772.59 ± 26.30 | 1367.76 ± 76.70 |
AE's are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment
| participants | Glycopyrrolate Inhalation Solution12.5μg | Glycopyrrolate Inhalation Solution 50μg | Glycopyrrolate Inhalation Solution 100μg | Glycopyrrolate Inhalation Solution 200μg | Glycopyrrolate Inhalation Solution 400μg | Placebo 0.5mL |
|---|---|---|---|---|---|---|
| subjects who died | 0 | 0 | 0 | 0 | 0 | 0 |
| subjects with treatment emergent SAEs | 0 | 0 | 1 | 0 | 0 | 0 |
| Subjects whodiscontinued due to an AE | 2 | 2 | 2 | 0 | 0 | 0 |
| subjects with treatment emergent AEs | 16 | 14 | 17 | 15 | 13 | 14 |
Vital signs were measured at screening and at each Treatment Visit pre-dose (within 30 minutes prior to dose); post-dose at 30 minutes and 1, 2, 4, 8, 12 and 24 hours; and then at the post study assessment.
| Participants | Glycopyrrolate Inhalation Solution12.5μg | Glycopyrrolate Inhalation Solution 50μg | Glycopyrrolate Inhalation Solution 100μg | Glycopyrrolate Inhalation Solution 200μg | Glycopyrrolate Inhalation Solution 400μg | Placebo 0.5mL |
|---|---|---|---|---|---|---|
| Number of Subjects With Clinically Significant Abnormal Vital Signs Reported During the Study | 0 | 0 | 0 | 0 | 0 | 0 |
Clinical safety lab parameters were collected at screening and at the post study assessment. Any laboratory values that were out of range of normal reference values were evaluated by the Investigators.
| number of events | Glycopyrrolate Inhalation Solution12.5μg | Glycopyrrolate Inhalation Solution 50μg | Glycopyrrolate Inhalation Solution 100μg | Glycopyrrolate Inhalation Solution 200μg | Glycopyrrolate Inhalation Solution 400μg | Placebo 0.5mL |
|---|---|---|---|---|---|---|
| Number of Clinically Significant Abnormal Laboratory Results Reported During the Study | 0 | 0 | 0 | 0 | 0 | 0 |
ECGs were recorded at screening and at each study treatment visit pre-dose (within 30 minutes prior to dose); post-dose at 30 minutes and 1, 2, 4, 8, 12 and 24 hours; and then at the post study assessment.
| Participants | Glycopyrrolate Inhalation Solution12.5μg | Glycopyrrolate Inhalation Solution 50μg | Glycopyrrolate Inhalation Solution 100μg | Glycopyrrolate Inhalation Solution 200μg | Glycopyrrolate Inhalation Solution 400μg | Placebo 0.5mL |
|---|---|---|---|---|---|---|
| Number of Subjects With Clinically Significant ECG Parameters Reported During the Study | 0 | 0 | 0 | 0 | 0 | 0 |
AE's are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment
| percentage of participants | Glycopyrrolate Inhalation Solution12.5μg | Glycopyrrolate Inhalation Solution 50μg | Glycopyrrolate Inhalation Solution 100μg | Glycopyrrolate Inhalation Solution 200μg | Glycopyrrolate Inhalation Solution 400μg | Placebo 0.5mL |
|---|---|---|---|---|---|---|
| Percentage of Subjects With Treatment Emergent AEs | 41.0 | 36.8 | 45.9 | 40.5 | 35.1 | 37.8 |
Collected over 0-69 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Glycopyrrolate Inhalation Solution12.5μg | — | 0/39 (0%) | 13/39 (33.3%) |
| Glycopyrrolate Inhalation Solution 50μg | — | 0/38 (0%) | 9/38 (23.7%) |
| Glycopyrrolate Inhalation Solution 100μg | — | 1/37 (2.7%) | 10/37 (27%) |
| Glycopyrrolate Inhalation Solution 200μg | — | 0/37 (0%) | 10/37 (27%) |
| Glycopyrrolate Inhalation Solution 400μg | — | 0/37 (0%) | 10/37 (27%) |
| Placebo 0.5mL | — | 0/37 (0%) | 10/37 (27%) |
| Event | Glycopyrrolate Inhalation Solution12.5μg | Glycopyrrolate Inhalation Solution 50μg | Glycopyrrolate Inhalation Solution 100μg | Glycopyrrolate Inhalation Solution 200μg | Glycopyrrolate Inhalation Solution 400μg | Placebo 0.5mL |
|---|---|---|---|---|---|---|
| groin painGeneral disorders | 0/39 | 0/38 | 1/37 | 0/37 | 0/37 | 0/37 |
| Event | Glycopyrrolate Inhalation Solution12.5μg | Glycopyrrolate Inhalation Solution 50μg | Glycopyrrolate Inhalation Solution 100μg | Glycopyrrolate Inhalation Solution 200μg | Glycopyrrolate Inhalation Solution 400μg | Placebo 0.5mL |
|---|---|---|---|---|---|---|
| headacheNervous system disorders | 6/39 | 5/38 | 5/37 | 7/37 | 6/37 | 4/37 |
| coughRespiratory, thoracic and mediastinal disorders | 3/39 | 2/38 | 5/37 | 3/37 | 3/37 | 5/37 |
| dyspnoeaRespiratory, thoracic and mediastinal disorders | 3/39 | 2/38 | 1/37 | 1/37 | 1/37 | 2/37 |
| skin injuryInjury, poisoning and procedural complications | 0/39 | 0/38 | 0/37 | 0/37 | 0/37 | 2/37 |
| chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 2/39 | 1/38 | 0/37 | 0/37 | 0/37 | 0/37 |
Intent to treat population same as safety population -not full analysis set
| Age, Categorical(Participants) | Total Participants |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 29 |
| >=65 years | 13 |
| Age, Continuous(years) | Total Participants |
|---|---|
| Mean | 62.0 ± 6.99 |
| Sex: Female, Male(Participants) | Total Participants |
|---|---|
| Female | 15 |
| Male | 27 |
| Ethnicity (NIH/OMB)(Participants) | Total Participants |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 42 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Total Participants |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 41 |
| More than one race | 1 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Total Participants |
|---|---|
| United Kingdom | 42 |
No study locations are listed for this record.
The record gives a start of Jul 2010, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2018, 7 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
Sunovion Respiratory Development Inc. →